DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Long-term effects of doxazosin, finasteride, and combination therapy on quality of life in men with benign prostatic hyperplasia.

Author(s): Fwu CW, Eggers PW, Kaplan SA, Kirkali Z, Lee JY, Kusek JW.

Affiliation(s): Social & Scientific Systems, Inc., Silver Spring, MD. Electronic address: cfwu@s-3.com.

Publication date & source: 2013, J Urol. ,

PURPOSE: To examine the effects of doxazosin, finasteride and combination therapy among men with benign prostatic hyperplasia (BPH) on quality of life (QoL) assessed by a general (the Medical Outcomes Study Short-Form-36 [MOS-SF-36]) and two disease-specific instruments (the BPH Impact Index [BII] and the International Prostate Symptom Score [IPSS]-QoL) over 4 years. MATERIALS AND METHODS: The Medical Therapy of Prostatic Symptoms (MTOPS) Study was a multi-center, randomized, double-blind, placebo-controlled clinical trial with a primary outcome of time-to-BPH progression. Change in QoL was a secondary outcome. A total of 2,872 men enrolled in the MTOPS Study who had three baseline QoL measures and at least one follow-up measure by any of the QoL instruments were analyzed. RESULTS: Compared with men assigned to placebo, men assigned to doxazosin and combination experienced a statistically significant improvement in the BII at year 4. Men assigned to each of the drug groups also experienced a significant improvement in the IPSS-QoL compared with those assigned to placebo. Considering longitudinal changes over 4 years, a significant improvement in BII and IPSS-QoL scores was observed in men assigned to the drug groups compared with those assigned to placebo. However, there were no significant differences for the MOS-SF-36 subscales and summary scores when drug groups were compared with the placebo group. CONCLUSIONS: QoL of men treated with doxazosin, finasteride, and the drugs combined generally improved when assessed with the BII and the IPSS-QoL compared with those treated with placebo. QoL did not show improvement when measured by the MOS-SF-36.

Page last updated: 2013-02-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012